Asthma Exacerbations
Conditions
Keywords
asthma exacerbation, prednisone, randomized controlled trial
Brief summary
Patients with severe asthma frequently experience exacerbations of their disease. The heterogeneity of asthma exacerbations represents a major challenge for patients and healthcare providers, making treatment difficult. Current guidelines recommend varying doses of short-term oral corticosteroids (OCS) as first-line treatment for asthma exacerbations. However, studies supporting the optimal dose of OCS to treat asthma exacerbations are rare. This study aims to evaluate the feasibility, acceptability, and safety of a randomized clinical trial with different OCS regimens for patients and physicians. Additionally, evaluate the success rate of different OCS dosages to support power calculations for a non-inferiority trial. In this pilot, parallel, randomized, controlled study, patients with severe asthma exacerbation, considered to require treatment with OCS according to physician judgment after a complete evaluation will be randomized to 1) 3 days of 50 mg prednisone followed by 7 days of placebo, 2) 3 days of 50 mg prednisone and 4 days of 25 mg prednisone followed by 3 days of placebo, or 3) 5 days of 50 mg prednisone and 5 days of 25 mg prednisone. Randomized patients will be assessed for daily symptoms and overall perception of well-being, in addition to asthma control, quality of life as well as additional medical visits. Lung function and inflammation will also be measured. Feasibility and acceptability will be defined by a participation rate \>80%, while safety will be defined as an increase in OCS doses in \<20% of patients in one arm or an emergency room visit in \<10% of patients in one arm. Success will be defined as no increased or prolonged doses of OCS, no re-consultation for OCS or escalation to antibiotics, reduction of symptoms, and return of lung function to \>80% of its optimal level. In addition to determining the feasibility and safety of different OCS regimens to treat asthma exacerbations, this trial will help us determine the optimal design for a randomized clinical trial using different OCS regimens. The exacerbation clinic is already operational with 4 to 5 patients/week assessed and treated. We have all the resources on site to carry out this project.
Interventions
DRUGPrednisone
Either 150 mg over 3 days or 250 mg over 7 days or 350 mg over 10 days
Sponsors
Andréanne Côté
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female volunteers * 18 years of age or older * Assessed for a severe asthma exacerbation * Being prescribed OCS for the management of their exacerbation * Able to comprehend and follow all required study procedures * Able to understand and give written informed consent and have signed a written informed consent form (ICF) approved by the REB
Exclusion criteria
* For females, are pregnant, or lactating * Respiratory comorbidities other than asthma, including bronchiectasis (non-CF) or asthma-COPD overlap (ACO) * FEV1 \<40% of personal best or \<1 Li * OCS-dependent * Asthma exacerbation in the 4 weeks preceding the study visit * Concomitant disease, health condition, and/or lifestyle activities that could interfere with the conduct of the study, or for which the treatment might interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study, including, but not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease. These include, but are not restricted to: heart failure, previous bipolar decompensation with prednisone, severe blood hypertension, uncontrolled diabetes, pneumonia. * Unwilling or unable to comply with the study protocol for any other reason
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acceptability | 9 months | Acceptability for subjects will be defined by the proportion of subjects agreeing to the study whereas acceptability for physicians will be defined by the proportion of subjects for whom the physicians prescribe OCS and is willing to enroll them in the study. |
| Enrollment rate | 9 months | Period of time needed to recruit the total number of subjects. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety outcomes: Hospitalization | 14 days | Was the patient hospitalized between day of exacerbation and day 14? |
| Safety outcomes: Unscheduled medical visits | 14 days | Did the participant go for an unscheduled medical visit between day of exacerbation and day 14? |
| Safety outcomes: New or increase antibiotics | 14 days | Was the participant prescribed new antibiotics treatment or had to increase antibiotics between day of exacerbation and day 14? |
| Safety outcomes: increased or prolonged OCS dose | 14 days | Has the participant had to increase or prolong his OCS dose? |
| Safety outcome: emergency room visits | 14 days | Did the participant go to the emergency room visit between day of exacerbation and day 14. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Success rate | 14 days | Success parameters will include increased or prolonged OCS dose, re consultation for OCS, new, increased or prolonged antibiotics, change in ACQ6 score between baseline and 14 days, and change in FEV1 between baseline and 14 days. |
Contacts
Primary ContactAndréanne Côté, MD-MSc
Backup ContactMarie-Eve Boulay, MSc
Outcome results
None listed